Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes
Patient- and tumour-specific characteristics strongly influence survival in mPAC patients receiving systemic therapy. These findings can support a more detailed risk stratification at diagnosis to optimise treatment selection, avoid both over- and undertreatment, and align care with individual patient expectations and values for more personalised treatment strategies.
Authors
- Liselot Valkenburg‐van Iersel (ORCID: https://orcid.org/0000-0003-2925-9908)
- Judith de Vos‐Geelen (ORCID: https://orcid.org/0000-0003-2578-1766)
- Merlijn U.J.E. Graus (ORCID: https://orcid.org/0000-0002-3645-1458)
- Lydia GM van der Geest
- Aniek E. van Diepen (ORCID: https://orcid.org/0009-0007-0192-5354)
- Jeanin E. van Hooft
- Marjolein Y.V. Homs
- Miriam L Wumkes
- Ignace H.J.T. de Hingh
- Thijmen Broekman
- Johanna W. Wilmink
- Casper W.F. van Eijck
Institutions
- Radboud University Nijmegen (NL)
- Leiden University Medical Center (NL)
- Maastricht University Medical Centre (NL)
- Catharina Ziekenhuis (NL)
- Erasmus MC (NL)
- Netherlands Comprehensive Cancer Organisation (NL)
- Erasmus MC Cancer Institute (NL)
- Amsterdam University Medical Centers (NL)
- Jeroen Bosch Ziekenhuis (NL)
- Amsterdam University of Applied Sciences (NL)
- University of Amsterdam (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1016/j.ejca.2026.116263
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00